Earth Science Tech Inc. (OTC: ETST) continues to strengthen its operational and financial frameworks, positioning itself as an outlier in the over-the-counter (OTC) market. The company, a strategic holding company in the healthcare, pharmacy, and telemedicine sector, has reported year-over-year growth in revenue and gross profits since fiscal year 2024, a trajectory attributed to careful strategic investments and acquisitions that have not added debt to its balance sheet. This performance stands in contrast to the typical risks associated with OTC stocks, such as the lack of reliable information highlighted by Investopedia (https://ibn.fm/4qcql).
Earth Science Tech's most recent annual report for the fiscal year ended March 31, 2026, shows revenue of $35.7 million, up from $33.1 million in FY2025 and $11.95 million in FY2024 (https://ibn.fm/gmnx1). Gross profit grew to $25.5 million in FY2026 from $23.5 million in FY2025 (https://ibn.fm/cUtl7). The company attributes this growth to its acquisition strategy, including the purchase of Avenvi, which created a subsidiary that develops, manages, and finances real estate. This subsidiary owns property that houses ETST’s Texas pharmacy, providing hard asset backing that is rare among OTC-listed firms.
Unlike many penny stocks that suffer from opaque financial reporting and lack of tangible assets, Earth Science Tech maintains a robust corporate structure with timely filings and vertical integration. The company's ownership of physical real estate and its debt-free expansion strategy mitigate the risks often associated with OTC investments. By combining strong financial results with hard assets, ETST offers a level of transparency and stability that is uncommon in the OTC market, potentially attracting investors seeking value beyond the stigma of penny stocks.
